Zymeworks Inc. (NYSE: ZYME) Files An 8-K Other EventsItem 8.01, “Other Events.”
On December 8, 2018, Zymeworks Inc. announced the presentation of IND-enabling data for ZW49, its novel biparatopic HER2-targeted ADC, at the San Antonio Breast Cancer Symposium in San Antonio, Texas.
Zymeworks Inc. ExhibitEX-99.1 2 ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Zymeworks Submits Investigational New Drug (IND) Application for ZW49 and Presents IND‑Enabling Studies at the San Antonio Breast Cancer Symposium ● ZW49 combines Azymetric™ and ZymeLink™ technologies to broaden the therapeutic window of antibody-drug conjugates (ADCs) ● Complete tumor regressions observed in high and low HER2-expressing models ● Superior preclinical efficacy compared to approved HER2 ADCs ● Toxicology results support clinical dosing well above predicted efficacy levels ● Potential to address unmet need in high and low HER2-expressing cancers,…To view the full exhibit click here
